AR046917A1 - A COMPOSITION THAT INCLUDES ANTAGONISTS OF THE BRADICININE B1 RECEIVER - Google Patents

A COMPOSITION THAT INCLUDES ANTAGONISTS OF THE BRADICININE B1 RECEIVER

Info

Publication number
AR046917A1
AR046917A1 ARP040103834A AR046917A1 AR 046917 A1 AR046917 A1 AR 046917A1 AR P040103834 A ARP040103834 A AR P040103834A AR 046917 A1 AR046917 A1 AR 046917A1
Authority
AR
Argentina
Prior art keywords
bradicinine
receiver
composition
peptides
conjugated peptides
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Gordon Ng
Yue-Sheng Li
Colin V Gegg
Tjomas Storz
Yuelie Lu
Amico Derin C D
Benny C Askew Jr
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR046917A1 publication Critical patent/AR046917A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a ciertos péptidos y péptidos conjugados biologicamente activos que se pueden utilizar en medidas terapéuticas y profilácticas contra enfermedades o cuadros relacionados con B1 como agente causativo. En una forma de realizacion preferida, se proporcionan péptidos conjugados con PEG biologicamente activos. En un aspecto de la presente, los péptidos conjugados con PEG farmacologicamente activos resultan de utilidad para tratar la inflamacion o el dolor.This refers to certain biologically active conjugated peptides and peptides that can be used in therapeutic and prophylactic measures against diseases or conditions related to B1 as the causative agent. In a preferred embodiment, biologically active PEG conjugated peptides are provided. In one aspect of the present, pharmacologically active PEG conjugated peptides are useful for treating inflammation or pain.

ARP040103834 2003-10-22 2004-10-22 A COMPOSITION THAT INCLUDES ANTAGONISTS OF THE BRADICININE B1 RECEIVER AR046917A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51391303P 2003-10-22 2003-10-22
US53892904P 2004-01-24 2004-01-24

Publications (1)

Publication Number Publication Date
AR046917A1 true AR046917A1 (en) 2006-01-04

Family

ID=36603114

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103834 AR046917A1 (en) 2003-10-22 2004-10-22 A COMPOSITION THAT INCLUDES ANTAGONISTS OF THE BRADICININE B1 RECEIVER

Country Status (2)

Country Link
AR (1) AR046917A1 (en)
IS (1) IS8465A (en)

Also Published As

Publication number Publication date
IS8465A (en) 2006-05-15

Similar Documents

Publication Publication Date Title
ECSP066575A (en) BRADIQUININE B1 RECEIVER ANTAGONISTS
AR068185A1 (en) COMPOSITIONS OF LAMOTRIGIN ORAL DISINTEGRATION TABLETS
CL2008001268A1 (en) Compounds derived from n- [6-amino-5-aryl-pyridin-2-yl] -carboxamide; pharmaceutical composition that includes them; combined pharmaceutical composition comprising them together with another additional pharmacological agent; and use them in the treatment of pain.
CR20110596A (en) SUBLINGUAL COMPOSITIONS OF DEXMEDETOMIDINE AND METHODS OF USE OF THEM
CL2008001114A1 (en) Compounds derived from benzimidazole; pharmaceutical composition; and use in the treatment of diseases such as overactive bladder, pain, obesity, seizures, among others.
GT200700034A (en) PHARMACEUTICAL COMPOSITIONS OF ANTI-BODY ANTAGONISTS ANTI-CD40
AR053651A1 (en) COMBINED TREATMENT OF ANTIBODY ANTICTLA4 R AROMATASE INHIBITOR FOR BREAST CANCER
AR048878A1 (en) TOPIC COMPOSITIONS OF METADONA AND METHODS FOR USE
AR048833A1 (en) PROCEDURE FOR THE TREATMENT OF PREMENSTRUAL DISORDERS AND OTHER FEMALE SEXUAL DISORDERS
CL2008000893A1 (en) Oral care composition comprising an effective amount of a basic amino acid and an antibacterial agent; use in the antibacterial treatment of the oral cavity.
AR052854A1 (en) METHOD TO REDUCE THE INFLAMMATION OF THE ORAL FABRIC USING MAGNOLIA EXTRACT
CL2011003160A1 (en) Heterocyclic derived compounds, cb2 modulators; pharmaceutical composition comprising them; and use in the treatment of rheumatic, autoimmune, inflammatory diseases, pain, among others.
DOP2005000248A (en) CYTOTOXIC AGENTS WHO UNDERSTAND NEW.
CO6480985A2 (en) FORMULATIONS FOR THE TREATMENT OF DEEP TISSULAR PAIN
CL2020000220A1 (en) Compositions comprising amino acids for use in the treatment of diseases related to mitochondrial dysfunction.
AR065581A1 (en) IMPROVEMENTS IN MEDICINAL COMPOSITIONS OR RELATED TO THE SAME
PA8654201A1 (en) CYTOTOXIC AGENTS UNDERSTANDING NEW TAXANS MODIFIED IN C-2
ECSP109960A (en) GEL CONTAINING PYRFENIDONE
HN2003000206A (en) PHARMACEUTICAL COMPOSITION THAT HAS A DISTRIBUTION AND UNIFORM POWER OF FARMACO
CL2008002545A1 (en) Phenoxy-benzyl-carbamoyl derived compounds; pharmaceutical composition; process for preparing the pharmaceutical composition; and its use in the treatment of pain.
CO6771406A2 (en) A combined composition
AR045783A1 (en) PHARMACEUTICAL COMPOSITION INCLUDING A P2X7 RECEIVER ANTAGONIST AND AN NON-STEROID ANTI-INFLAMMATORY DRUG
AR044350A1 (en) MICROENCAPSULATED ANALGESIC HOSE AND TOPICO PATCH FOR PAIN TREATMENT
AR048806A1 (en) USE OF CARIOFILENES IN THE PREPARATION OF MEDICINES AND TREATMENT OF BODY INFLAMMATION AND INFLAMMATORY PAIN AFFECTIONS
CL2008001477A1 (en) Pharmaceutical composition composed of the synergistic combination of an anticonvulsant agent such as gabapentin and a non-steroidal anti-inflammatory agent such as meloxicam, the concentration ranges present for gabapentin are 3 to 300 mg and 0.1 to 30 mg for meloxicam; and use to treat neuropathic pain

Legal Events

Date Code Title Description
FA Abandonment or withdrawal